299 related articles for article (PubMed ID: 18332674)
1. Developmental effects of 3,4-methylenedioxymethamphetamine: a review.
Skelton MR; Williams MT; Vorhees CV
Behav Pharmacol; 2008 Mar; 19(2):91-111. PubMed ID: 18332674
[TBL] [Abstract][Full Text] [Related]
2. Learning and memory after neonatal exposure to 3,4-methylenedioxymethamphetamine (ecstasy) in rats: interaction with exposure in adulthood.
Cohen MA; Skelton MR; Schaefer TL; Gudelsky GA; Vorhees CV; Williams MT
Synapse; 2005 Sep; 57(3):148-59. PubMed ID: 15945064
[TBL] [Abstract][Full Text] [Related]
3. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
[TBL] [Abstract][Full Text] [Related]
4. Neonatal 3,4-methylenedioxymethamphetamine (ecstasy) alters dopamine and serotonin neurochemistry and increases brain-derived neurotrophic factor in the forebrain and brainstem of the rat.
Koprich JB; Campbell NG; Lipton JW
Brain Res Dev Brain Res; 2003 Dec; 147(1-2):177-82. PubMed ID: 14741762
[TBL] [Abstract][Full Text] [Related]
5. MDMA (3,4-methylenedioxymethamphetamine) or ecstasy: the contemporary human and animal research perspective.
Parrott AC; Marsden CA
J Psychopharmacol; 2006 Mar; 20(2):143-6. PubMed ID: 16510473
[No Abstract] [Full Text] [Related]
6. (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies.
McCann UD; Eligulashvili V; Ricaurte GA
Neuropsychobiology; 2000; 42(1):11-6. PubMed ID: 10867551
[TBL] [Abstract][Full Text] [Related]
7. Increased effects of 3,4-methylenedioxymethamphetamine (ecstasy) in a rat model of depression.
Jaehne EJ; Majumder I; Salem A; Irvine RJ
Addict Biol; 2011 Jan; 16(1):7-19. PubMed ID: 20192951
[TBL] [Abstract][Full Text] [Related]
8. 3,4-Methylenedioxymethamphetamine administration on postnatal day 11 in rats increases pituitary-adrenal output and reduces striatal and hippocampal serotonin without altering SERT activity.
Williams MT; Schaefer TL; Ehrman LA; Able JA; Gudelsky GA; Sah R; Vorhees CV
Brain Res; 2005 Mar; 1039(1-2):97-107. PubMed ID: 15781051
[TBL] [Abstract][Full Text] [Related]
9. Long-term behavioral consequences of prenatal MDMA exposure.
Thompson VB; Heiman J; Chambers JB; Benoit SC; Buesing WR; Norman MK; Norman AB; Lipton JW
Physiol Behav; 2009 Mar; 96(4-5):593-601. PubMed ID: 19162054
[TBL] [Abstract][Full Text] [Related]
10. Neurotoxic effects of MDMA (ecstasy) on the developing rodent brain.
Dzietko M; Sifringer M; Klaus J; Endesfelder S; Brait D; Hansen HH; Bendix I; Felderhoff-Mueser U
Dev Neurosci; 2010 Aug; 32(3):197-207. PubMed ID: 20616555
[TBL] [Abstract][Full Text] [Related]
11. Cognitive impairments from developmental exposure to serotonergic drugs: citalopram and MDMA.
Schaefer TL; Grace CE; Braun AA; Amos-Kroohs RM; Graham DL; Skelton MR; Williams MT; Vorhees CV
Int J Neuropsychopharmacol; 2013 Jul; 16(6):1383-94. PubMed ID: 23308402
[TBL] [Abstract][Full Text] [Related]
12. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
Parrott AC
J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
[TBL] [Abstract][Full Text] [Related]
13. Increased responsiveness to MDMA in adult rats treated neonatally with MDMA.
Piper BJ; Meyer JS
Neurotoxicol Teratol; 2006; 28(1):95-102. PubMed ID: 16271852
[TBL] [Abstract][Full Text] [Related]
14. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview.
Gouzoulis-Mayfrank E; Daumann J
J Psychopharmacol; 2006 Mar; 20(2):188-93. PubMed ID: 16510477
[TBL] [Abstract][Full Text] [Related]
15. Dose concentration and spatial memory and brain mitochondrial function association after 3,4-methylenedioxymethamphetamine (MDMA) administration in rats.
Taghizadeh G; Mehdizadeh H; Lavasani H; Hosseinzadeh Ardakani Y; Foroumadi A; Halvaei Khankahdani Z; Moshtagh A; Pourahmad J; Sharifzadeh M; Rouini MR
Arch Toxicol; 2020 Mar; 94(3):911-925. PubMed ID: 32067070
[TBL] [Abstract][Full Text] [Related]
16. MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research.
Clemens KJ; McGregor IS; Hunt GE; Cornish JL
Drug Alcohol Rev; 2007 Jan; 26(1):9-15. PubMed ID: 17364831
[TBL] [Abstract][Full Text] [Related]
17. Acute 3,4-methylenedioxymethamphetamine(MDMA) administration produces a rapid and sustained suppression of immune function in the rat.
Connor TJ; McNamara MG; Finn D; Currid A; O'Malley M; Redmond AM; Kelly JP; Leonard BE
Immunopharmacology; 1998 Jan; 38(3):253-60. PubMed ID: 9506825
[TBL] [Abstract][Full Text] [Related]
18. Exposure to 3,4-methylenedioxymethamphetamine (MDMA) on postnatal days 11-20 induces reference but not working memory deficits in the Morris water maze in rats: implications of prior learning.
Vorhees CV; Reed TM; Skelton MR; Williams MT
Int J Dev Neurosci; 2004; 22(5-6):247-59. PubMed ID: 15380825
[TBL] [Abstract][Full Text] [Related]
19. Pre-treatment with 3,4-methylenedioxymethamphetamine (MDMA) causes long-lasting changes in 5-HT2A receptor-mediated glucose utilization in the rat brain.
Bull EJ; Porkess V; Rigby M; Hutson PH; Fone KC
J Psychopharmacol; 2006 Mar; 20(2):272-80. PubMed ID: 16510485
[TBL] [Abstract][Full Text] [Related]
20. Memory impairment in abstinent MDMA ("Ecstasy") users.
Bolla KI; McCann UD; Ricaurte GA
Neurology; 1998 Dec; 51(6):1532-7. PubMed ID: 9855498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
